The association between plasma adiponectin level and blood pressure remains inconclusive. Because obese subjects may have different mechanisms to regulate blood pressure, we hypothesized that obesity may be an important modifier. In order to minimize confounding effects from unidentified factors, a family-based design was employed to explore the relationship.
Adiponectin is an adipokine derived mainly from adipose tissue. 1 It plays an important role in the development of the metabolic syndrome and coronary arterial disease. [2] [3] [4] [5] [6] In animals, injections of adiponectin have been shown to improve insulin sensitivity and reduce plasma glucose and fatty-acid levels. 3, 6 Long-term administration of adiponectin has also been shown to result in weight loss in mice. 6 In humans, plasma adiponectin levels have been found to decrease in subjects with obesity, 4 diabetes mellitus, 5 dyslipidemia, 4 and coronary arterial disease. 2 Moreover, hypoadiponectinemia has been shown to predict the development of diabetes mellitus 7, 8 and coronary arterial disease. 9, 10 However, in contrast to these several consistent reports, the relationship between plasma adiponectin level and hypertension (the other important component of the metabolic syndrome) remains controversial. 4, [11] [12] [13] [14] [15] A recent report has demonstrated that hypoadiponectinemia is a predictor of the development of hypertension. 16 Three cross-sectional studies, including ours, have shown a negative association between plasma adiponectin level and blood pressure. 11, 12, 15 Similarly, another study in young men has also shown that subjects with high-to-normal blood pressure have lower serum adiponectin levels. 14 On the other hand, two other studies reported that there was no significant association between plasma adiponectin level and blood pressure. 4, 13 There is a good deal of evidence to suggest that a different mechanism operates to regulate blood pressure in obese subjects. [17] [18] [19] [20] [21] [22] For example, articles Plasma Adiponectin and Blood Pressure in genetically obese KKAy mice, adiponectin replenishment by adenovirus has been shown to ameliorate obesity-related hypertension. 23 Because the association studies in humans were done in different obesity ranges, we hypothesized that the relationship between plasma adiponectin level and blood pressure may depend on obesity.
Many other factors may also confound the relationship between plasma adiponectin level and blood pressure. If the confounders were identified, they might be controlled by statistical procedures. However, if these factors are not identified, they may be responsible for differences in results between studies, a phenomenon similar to the effect of "population stratification" in genetic analyses. 24 A family-based design could minimize the effects of such unidentified confounders, because siblings are of the same race, have similar genetic backgrounds, and have shared early-life environment. Previous studies of the relationship between plasma adiponectin level and blood pressure did not utilize a family-based design.
Therefore, in this study, we used a family-based design to examine the relationship between plasma adiponectin level and blood pressure in the context of the presence of obesity.
metHoDS

Study population and phenotypic characterization.
The SAPPHIRe (Stanford-Asian Pacific Program in Hypertension and Insulin Resistance) cohort has been previously described. 25, 26 Briefly, the study included concordant sibling pairs and discordant sibling pairs of either Japanese or Chinese descent. Concordant sibling pairs were those in which both siblings had high blood pressure (defined as having systolic blood pressure (SBP) ≥160 mm Hg or diastolic blood pressure (DBP) ≥95 mm Hg, or taking two antihypertensive medications, or taking one antihypertensive medication and having either SBP ≥140 or DBP ≥90 mm Hg). Discordant sibling pairs were those in which one sibling had high blood pressure (as defined earlier) and the other had low blood pressure (defined as having a BP in the bottom 30% of the age-and sex-adjusted BP distribution). The following exclusion criteria were applied: (i) one of the affected siblings of a pair was adopted (i.e., no parent in common) or the siblings had only one parent in common; (ii) both parents of the subjects had been treated for hypertension before the age of 60 (not applicable to discordant sibling pairs); (iii) subjects with diabetes (iv) subjects with severe kidney disease with serum creatinine >0.133 mmol/l not resulting from stones or prior infections, except those who had met inclusion criteria before the increase in creatinine levels; and (v) subjects with body mass index (BMI) >35 kg/m 2 . In addition, the following conditions were also considered to be causes for exclusion: (i) ongoing (or within the past 6 months) treatment for cancer; (ii) terminal illness (life expectancy <6 months); (iii) liver cirrhosis or any other documented chronic illness; and (iv) pregnancy or <6 months postpartum. In this report, a total of 1,048 subjects from 478 families were studied. The Institutional Review Board of each participating site approved the study, and all subjects provided written informed consent.
Blood pressure was recorded automatically in accordance with a common protocol using the DINAMAP Vital Signs Monitor (Model 1846 SX/P; Critikon, Tampa, FL) with Adult DuraCuff (CK2774), suitable for subjects with bicep circumference 23-33 cm. Subjects were seated quietly for 10 min in a chair, with feet on the floor and arm supported at heart level. Then three separate readings were taken by trained nurses, at 1-min intervals. The average of the second and the third readings was used in the subsequent analysis. Hypertension was defined as per the criteria described earlier. BMI was defined as weight (kg)/height (m 2 ). Obesity was defined as BMI ≥25 kg/m 2 in accordance with the criteria set by the Joint Committee of the International Association for the Study of Obesity, the International Obesity Task Force, and the World Health Organization on the basis of the Asia-Pacific regional reports. 27 Waist circumference was measured at the level of the umbilicus during mid-respiration with participants breathing quietly. The measurement was read to the nearest 0.1 cm.
A 75-g oral glucose tolerance test was administered to all the subjects. The concentrations of plasma glucose, total cholesterol, high-density lipoprotein, triglycerides, and insulin were measured in fasting samples. The updated computer models of homeostasis model assessment (HOMA2) were used for calculating the indices of insulin sensitivity (HOMA2 %S) 28 This model has a nonlinear solution, and incorporated the estimate of proinsulin secretion as well as renal glucose loss, thereby significantly improving the validity of the results. A high HOMA2 %S indicates better insulin sensitivity. Another index called insulin sensitivity index 0,120 (ISI 0,120 ) was calculated using data from the oral glucose tolerance test and body weight. 29 Like HOMA2 %S, a high ISI 0,120 also implies better insulin sensitivity. Fasting plasma adiponectin was measured using radioimmunoassay (LINCO Research, St Charles, MO).
Statistical analysis. All variables were summarized as mean values + s.d. in SI units, except for adiponectin levels (μg/ml), HOMA2 %S, and ISI 0,120 (mg·l 2 /mmol·mU·min). The distributions of continuous variables were examined, and log transformations of non-normally distributed variables were used in the analyses, where appropriate.
Logistic regression analyses were used for assessing the correlation of plasma adiponectin with the presence of hypertension, adjusting for age, sex, and standardized insulin sensitivity indices ((insulin sensitivity index − mean of insulin sensitivity index)/s.d. of insulin sensitivity index) in different models. Linear regression models were applied to analyze the relationship between plasma adiponectin level and SBP. In order to allow for family effect, a generalized estimating equations approach was adopted for modeling, assuming an exchangeable within-family correlation structure. 30 
reSULtS
Among the SAPPHIRe family members, there were 699 subjects with hypertension and 349 without. Their mean age was 50.4 ± 9.0 years. The subjects who had hypertension were found to be older, and had higher waist circumferences, BMIs, serum articles Plasma Adiponectin and Blood Pressure total cholesterol levels, triglyceride levels, and fasting plasma glucose levels, and lower serum high-density lipoprotein levels than those without hypertension ( Table 1) . They also showed poorer insulin sensitivity by indices of HOMA2 %S and ISI 0,120 . Plasma adiponectin level in those with hypertension was 5.99 ± 3.64 μg/ml, which was significantly lower than in those without hypertension (6.65 ± 3.86 μg/ml, P < 0.01).
In order to differentiate the impact of plasma adiponectin level on the risk of hypertension, we employed multivariate logistic regression analyses. After adjusting for age and sex, the plasma adiponectin level was negatively associated with the presence of hypertension ( Table 2 ). The odds ratio (OR) of hypertension was 0.92 (P < 0.001) for every 1 μg/ml increase in plasma adiponectin level. Similarly, as shown in Figure 1 , those with adiponectin levels below the 25th percentile (<3.7 μg/ml) and between the 25th and 50th percentiles (3.7-5.35 μg/ml) had significantly higher OR of hypertension after adjusting for age and sex than those above the 75th percentile (>7.75 μg/ml, Figure 1a) . Moreover, this negative association remained statistically significant after further adjusting for insulin sensitivity, i.e., for every 1 μg/ml increase in plasma adiponectin level, the OR of hypertension was 0.94 (P < 0.01) or 0.95 (P < 0.05) after adjusting for age, sex, and HOMA2 %S or ISI 0,120 ( Table 2) . For the purpose of comparing the independent effects of plasma adiponectin level and insulin sensitivity on the risk of hypertension, we used standardized variables in the models. The OR of hypertension associated with every 1-s.d. increase of plasma adiponectin level was 0.81 (95% confidence interval (CI) 0.70-0.95), after adjusting for age, sex, and standardized HOMA2 %S. This was similar (P = 0.38 by z-test) to the OR of hypertension for every 1-s.d. increase of HOMA2 %S (0.71, 95% CI 0.52-0.98) in the same model. However, in another model, the OR of hypertension for every 1-s.d. increase in plasma adiponectin level was 0.84 (95% CI 0.73-0.97), after adjusting for age, sex, and standardized ISI 0,120 . This OR was higher (P = 0.03 by z-test) than the OR associated with every 1-s.d. increase of ISI 0,120 (0.68, 95% CI 0.57-0.81). The results of the two z-tests suggested that the effect of plasma adiponectin levels on hypertension was not greater than that of insulin sensitivity. We also found that , insulin sensitivity index; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride. *P < 0.0001 between those with and those without hypertension; **P < 0.01 between those with and those without hypertension; ***P < 0.05 between those with and those without hypertension. either index of insulin sensitivity was an independent risk factor for hypertension in these models ( Table 2 ). The poorer the insulin sensitivity index HOMA2 %S, the higher the risk of hypertension after adjusting for age, sex, and adiponectin level (Figure 1b) . A similar result was observed when ISI 0,120 was used as the insulin sensitivity index (below 25th percentile, OR of hypertension = 4.39, 95% CI 2.82-6.85, 25th-50th percentile, OR = 1.94, 95% CI 1.33-2.82, 50th-75th percentile, OR = 1.45, 95% CI 1.00-2.11, above 75th percentile, OR = 1, all adjusted for age, sex, and adiponectin level). There were 349 subjects without hypertension. Among them, 112 subjects fulfilled the criteria of obesity and 237 subjects were not obese ( Table 3) . Plasma adiponectin levels were significantly lower in those with obesity, as compared with those without obesity (5.40 ± 3.03 vs. 7.23 ± 4.07, P < 0.001). In obese subjects, we found a statistically significant negative association between SBP and plasma adiponectin level after adjusting for age and sex (β = −0.56, P = 0.04, Figure 2a) . Further adjustment of BMI yielded similar results (β = −0.53, P = 0.047, Table 3 ). However, in non-obese subjects, the relationship was not statistically significant (Figure 2b and Table 3 ). Similar patterns were seen when considering HOMA2 %S as a confounder ( Table 3) . These results indicate a negative relationship, in obese subjects, between the plasma adiponectin level and SBP, independent of insulin sensitivity. In non-obese subjects, however, there was no statistically significant relationship between plasma adiponectin level and SBP. When DBP was used as a dependent variable, there was no significant relationship between DBP and plasma adiponectin in either of the groups, after adjusting for age, sex, and BMI.
DIScUSSIon
To the best of our knowledge, this is the first study to use a family-based design to analyze the relationship between adiponectin and blood pressure in order to minimize the effect of unidentified confounders and to increase statistical power. Our results demonstrated a negative association between plasma adiponectin level and the presence of hypertension, and this was in agreement with the report of the longitudinal follow-up study. 16 We also confirmed the hypothesis that the relationship between plasma adiponectin level and blood pressure depends on obesity. Furthermore, insulin sensitivity was shown to be an independent risk factor for hypertension.
In general, hypertension results from interactions of the central nervous system, the autonomic nervous system, the cardiovascular system, and the kidneys. The mechanisms of hypertension in obese subjects may be different from those who are lean, as suggested by various reports. Obese subjects have been shown to have higher norepinephrine levels in plasma 31 and in urine. 32 After weight reduction, a decrease in plasma norepinephrine levels has been correlated with a decrease in waist-to-hip ratio. 33 Mice with obesity induced by high-fat diets have been demonstrated to have a blunted insulin-mediated vascular response that is not present in their lean littermates. 20 In obese subjects, blood pressure has been found to be more sensitive to a high-salt diet. 21 After completing a weight reduction program, 36 of 51 obese subjects became less salt sensitive. In another study, dietary weight reduction resulted in a decrease in plasma renin and aldosterone levels, and also in mean arterial blood pressure. 22 Indeed, in this study we have demonstrated that the relationships between plasma adiponectin levels and blood pressure differ between obese and non-obese subjects (Figure 2 and Table 3 ). A negative association between plasma adiponectin level and SBP was significant only in obese subjects. Our results were supported by a report by Adamczak et al. They found that plasma adiponectin levels were significantly correlated to mean arterial pressure before adjusting for BMI. However, after adjusting for BMI, the relationship was no longer statistically significant. 15 Similar relationships have been observed between adiponectin and other components of the metabolic syndrome. Kantartzis et al. have reported that the association between plasma adiponectin levels and insulin sensitivity depends on obesity. 34 Moreover, the same group, in another study, showed that the relationships plasma adiponectin level with a favorable lipid profile, decreased inflammation, and reduced ectopic fat accumulation depend on adiposity. 35 In children, the relationships between plasma adiponectin, lipid profile, and insulin level were significant only in those who were not lean. 36 In genetically obese KKAy mice, adiponectin replenishment resulted in a decrease in SBP, 23 a finding with which our results are in concordance. In humans, Asian Indians have been shown to have both low-plasma adiponectin levels and blunted insulinmediated vascular responses. 37 After receiving treatment with pioglitazone, the non-diabetes subjects in this population group showed increases in plasma adiponectin levels, and their response of insulin-mediated vasodilatation demonstrated a trend toward normalization. 38 These data have suggested the possible existence of mechanisms that link hypoadiponectinemia with elevated blood pressure. In contrast, two studies have reported that the relationship between plasma adiponectin level and hypertension was independent of BMI. 12, 14 Both studies examined the relationship only in men. Kazumi et al. explored this in a population aged 18-26 years; these subjects were much younger than the age group in which hypertension is most prevalent. 14 In the report by Iwashima et al., hypoadiponectinemia was shown to be a risk factor for hypertension after adjusting for age, BMI, and total cholesterol levels. 12 However, the relatively low R 2 in the model (0.0754) indicates that many potential confounders were not included, further strengthening the benefit of a family-based study design. We showed that plasma adiponectin level is associated with blood pressure independent of insulin sensitivity (Tables 2  and 3) , which is in concordance with the results by Iwashima et al. 12 They analyzed subjects without diabetes mellitus and divided these subjects into two groups, those with and those without insulin resistance, as defined by HOMA insulin resistance index greater or less than 3, respectively. Both groups showed significant negative relationships between SBP and plasma adiponectin levels. In adiponectin-knockout mice, hypertension developed when they were fed a high-salt chow. 23 In agreement with our results, there was no change in insulin sensitivity in these mice, indicating that there may be another mechanism linking hypoadiponectinemia with hypertension, other than through the influence of insulin sensitivity.
In summary, our study, using a family-based study design, supports the hypothesis that both hypoadiponectinemia and poor insulin sensitivity are independent risk factors for hypertension. In those without hypertension, the relationship between plasma adiponectin level and blood pressure depended on obesity. Our results suggest that future work in exploring the mechanisms between hypoadiponectinemia and blood pressure should take obesity into consideration. Because adiponectin and its receptors are potential targets in treating metabolic syndrome, our results may be beneficial in identifying patients who could benefit from adiponectin therapy for hypertension, for example, those who are obese.
